Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of amivantamab alone and with chemotherapy in advanced or metastatic colorectal cancer
CTR20222772Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of amivantamab in colorectal adenocarcinoma (8 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Objective response rate, Dose-limiting toxicity incidence and 4 more. Started Jan 2023; status: active.
02
Drugs
amivantamab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20222772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222772.